COVID-19 Vaccination in Patients With Rheumatic Diseases

NATIONAL VACCINATION REGISTRY FOR SARS-CoV-2 IN PATIENTS WITH RHEUMATIC DISEASES OF THE ARGENTINE SOCIETY OF RHEUMATOLOGY

The Argentine Society of Rheumatology (SAR) set out to develop a national register of patients with rheumatic diseases who have received a SARS-CoV-2 vaccine in order to assess their efficacy and safety in this population.

This is an observational, longitudinal, multicenter study, including patients with rheumatic diseases who have been vaccinated for COVID-19 in Argentine or any country. Patients will be followed for 12 months and two evaluations will be performed, one at baseline and the other after the follow-up time is completed.

The aim of this registry is to evaluate the efficacy and safety of the SARS-CoV-2 vaccines in patients with rheumatic diseases.

Inclusion Criteria:

• Patients ≥ 18 years of age.
• Diagnosis of rheumatic disease treated or not with immunosuppressive agents
• Patients who have received at least one dose of a SARS-CoV-2 vaccine
• Signature of informed consent.

Exclusion Criteria:

• Patients who express their desire not to participate in the study or who are unable to give their informed consent.